DURHAM, N.C.--(BUSINESS WIRE)--Jul 30, 2020--

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination diagnostic for the magnetic resonance imaging (MRI) market, announces a number of presentations highlighting the use of hyperpolarized Xenon 129 (“ 129 Xe”) will be made by leading academic researchers at the upcoming American Thoracic Society (“ATS”) virtual conference and the International Society for Magnetic Resonance in Medicine (“ISMRM”) virtual conference. The ATS and ISMRM conferences are taking place between August 5-10, 2020 and August 8-14, 2020, respectively.

Over 40 abstracts related to the use of hyperpolarized 129 Xe were accepted for presentation at ATS 2020. The abstracts listed below are among those that will be presented as posters on Wednesday, August 5, 2020:

ATS 2020 Abstract Title and Lead Author

 

Poster Number

 

Session Number

Coleman EM et al. Hyperpolarized 129 Xe Identifies Ventilation Responders to Glycopyrrolate/Formoterol Furmarate in Chronic Obstructive Lung Disease

 

523

 

D28

Bier EA et al. Monitoring Response to Inhaled Prostacyclin Therapy with 129 Xenon MR Imaging and Spectroscopy in Patients with Pulmonary Hypertension

 

593

 

B56

Neidbalski PJ et al. Hyperpolarized 129 Xe MRI of Regional Capillary-Level Cardio-Pulmonary Dynamics Predict Outcomes in IPF Patients

 

622

 

A68

Bier EA et al. Noninvasive Diagnosis of Pulmonary Hypertension with Hyperpolarized 129 Xe Magnetic Resonance Imaging and Spectroscopy

 

633

 

B58

Mummy D et al. Hyperpolarized Xe-129 MRI Measures of Gas Exchange in Non-specific Interstitial Pneumonia

 

705

 

D110

Wang Z et al. Spatial Correlation of 129 Xenon Gas Exchange MRI with 99m Tc Perfusion Scintigraphy

 

706

 

D110

Wang Z et al. Using 129 Xenon MR Gas Exchange MRI to Measure the Membrane and Capillary Components of DL CO and K CO

 

707

 

D110

Mummy D et al. Hyperpolarized 129 Xe MRI is sensitive to therapy response in idiopathic pulmonary fibrosis

 

713

 

D110

Shim YM et al. Positive Results from Two Randomized Phase III Trials Assessing Hyperpolarized 129Xenon Gas MRI as a Measure of Regional Lung Function as Compared to Imaging with 133Xenon Scintigraphy

 

1027

 

B39

Presentations of the following accepted abstracts will be delivered at ISMRM on the following days:

ISMRM 2020 Abstract Title and Lead Author

 

Program
Number

 

Session Name

Date

Bier EA et al. Noninvasive Diagnosis of Pulmonary Hypertension with Hyperpolarized 129 Xe Magnetic Resonance Imaging and Spectroscopy

 

2283

 

Hyperpolarized Gas/Lung MRI

August 8-14

Mummy D et al. Hyperpolarized 129 Xe MRI Measures of Gas Exchange in Non-specific Interstitial Pneumonia

 

2291

 

Thoracic & Breast MRI

August 8-14

Niedbalski PJ et al. Imaging Regional Capillary Cardio-Pulmonary Blood Flow Dynamics using Hyperpolarized 129 Xe MRI and Keyhole Reconstruction

 

0432

 

Thoracic MRI

August 11

Rankine L et al. Quantitative dose-dependent changes in regional lung function after radiation therapy detected using xenon-129 gas exchange MRI

 

0431

 

Thoracic MRI

August 11

Lu J et al. Bias field correction in hyperpolarized 129 Xe ventilation imaging

 

0451

 

Pulmonary Power

August 11

Wang Z et al. A model for interpreting hyperpolarized 129 Xe exchange MRI

 

0443

 

Pulmonary Power

August 11

Additionally, Talissa Altes, MD, Professor and Chair of Radiology at the University of Missouri will be delivering a presentation on Xenon lung magnetic resonance imaging (MRI) during the Lung/Thoracic MRI Session W-02 during ISMRM. Session W-02 takes place on Tuesday, August 11, 2020 from 1:45 to 2:30 p.m. ET.

Richard Hullihen, Chief Executive Officer of Polarean commented:“We are pleased to see 129 Xenon in MRI highlighted at these key scientific meetings. It is a testament to the growing interest in exploring hyperpolarized 129 Xenon as a way of advancing the use of MRI in a non-invasive, non-ionizing functional imaging platform to assist with the early diagnosis of respiratory diseases. As well as this, it can be used to monitor progression and therapeutic response in the patient. Many of the projects being presented at these two leading conferences have made use of Polarean’s products to conduct research, highlighting the growing academic acceptance of the Company’s technology. We hope that the inclusion of so many sessions on 129 Xenon will continue to showcase Polarean’s important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system.”

About Polarean ( www.polarean.com )

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas ( 129 Xe) as an imaging agent to visualize ventilation. 129 Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging 129 Xe in the MRI system. The development of these coils by the Group facilitates emerging applications.

CONTACT: Polarean Imaging plc

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Jonathan Allis, ChairmanWalbrook PR

Tel: +44 (0)20 7933 8780 orpolarean@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893 / +44 (0)7876 741 001

KEYWORD: NORTH CAROLINA EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY TECHNOLOGY OTHER HEALTH HEALTH GENERAL HEALTH RADIOLOGY MEDICAL DEVICES RESEARCH HOSPITALS SCIENCE HARDWARE

SOURCE: Polarean Imaging plc

Copyright Business Wire 2020.

PUB: 07/30/2020 08:00 AM/DISC: 07/30/2020 08:00 AM

Copyright Business Wire 2020.

0
0
0
0
0